QUARTERLY ACTIVIT Y REPORT SYDNEY, AUSTRALIA 30 SEPTEMBER 2026 HIGHLIGHTS OF THE QUARTER During and since the quarter ending 30 September 2026 Cash Position SECuRE Trial The Company remains well funded with a cash position of The Cohort Expansion (Main Group) of the Phase I/IIa SECuRE $152.9...
Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX ·
6ix is reading this filing.
Clarity Pharmaceuticals Ltd. on 6ix
Earlier from Clarity Pharmaceuticals
- Ph III CLARIFY trial target number of participants achieved
- SECuRE update
- Bioshares Biotech Summit Presentation
- Clarity Pharmaceuticals Announces SECuRE Trial Update on 8 GBq 67Cu-SAR-bisPSMA dose level with two additional complete responses
- Data on SAR-bisPSMA to be presented at EANM
